Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation

Bone Marrow Transplantation
V PavoneA Liso

Abstract

Haemopoietic stem cell therapy is an increasingly adopted procedure in the treatment of patients with malignant lymphoma. In this retrospective analysis, we evaluated 262 patients, 57 (22%) with Hodgkin's and 205 (78%) with non-Hodgkin's lymphomas (NHL), and 665 harvesting procedures in order to assess the impact of poor mobilization on survival and to determine the factors that may be predictive of CD34(+) poor mobilization. The mobilization chemotherapy regimens consisted of high-dose cyclophosphamide in 92 patients (35.1%) and a high-dose cytarabine-containing regimen (DHAP in 87 patients -(33.2%), MAD in 83 (31.7%)). The incidence of poor mobilizers (<2 x 10(6) CD34(+) cells/kg) was 17.9% overall, with a 10% of very poor mobilizers (< or = 1 x 10(6)/kg). Refractory disease status and chemotherapeutic load (>3 regimens) before mobilization played a negative role and were associated with poor mobilization. Survival analysis of all harvested patients showed an overall survival at 3 years of 71% in good mobilizers vs 33% in poor mobilizers (P=0.002). The event-free survival at 3 years was 23% in poor mobilizers and 58% in good mobilizers (P=0.04). We conclude that in NHL patients, poor mobilization status is predictive of survi...Continue Reading

References

Jan 1, 1993·Journal of Hematotherapy·A KessingerJ O Armitage
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C ElliottE J Kanfer
Sep 19, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A BrownJ DiPersio
Dec 16, 1998·Bone Marrow Transplantation·N H RussellA P Haynes
Nov 4, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·K E Stockerl-GoldsteinR S Negrin
Mar 29, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·I N MicallefT A Lister
Oct 2, 2003·Bone Marrow Transplantation·S SeropianD L Cooper
Nov 25, 2003·Hematology·Michele H Cottler-FoxSteven Devine
Dec 31, 2003·Journal of Clinical Apheresis·Sang Kyun SohnKyu Bo Lee

❮ Previous
Next ❯

Citations

Jan 14, 2009·Bone Marrow Transplantation·W BensingerJ M McCarty
Dec 18, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Sibel HacıoğluAli Keskin
Jul 13, 2012·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Nicola PiccirilloGina Zini
Sep 17, 2011·Pathology·L Bik ToIan D Lewis
Jun 1, 2011·Experimental Hematology·Mohamad Mohty, Anthony D Ho
Dec 7, 2010·Best Practice & Research. Clinical Haematology·John F DiPersio
Nov 28, 2008·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Alfredo MendroneFrederico Luiz Dulley
Mar 13, 2016·Revista brasileira de hematologia e hemoterapia·Marco Aurélio Salvino, Jefferson Ruiz
Mar 18, 2011·European Journal of Haematology·Grzegorz W BasakUNKNOWN Central and Eastern European Leukaemia Group (CELG)
Feb 1, 2013·Transfusion·Yvette C TanhehcoUna O'Doherty
Aug 27, 2010·European Journal of Haematology·Esa Jantunen, Gunnar Kvalheim
Jun 16, 2011·American Journal of Hematology·Grzegorz W BasakUNKNOWN Central and Eastern European Leukemia Group (CELG)
Jun 24, 2015·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Hakan GokerYahya Buyukasik
May 6, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Manuel AfableUday Popat
Jan 22, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Richard T MaziarzBrian J Bolwell
Jan 21, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Dawn SheppardJason Tay
Nov 21, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Patrick WuchterAnthony D Ho
Aug 28, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ivana N M MicallefShaji Kumar
Jul 28, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Immacolata AttolicoAttilio Olivieri
May 21, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul ShaughnessySimon Pickard
Jun 28, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nandita KheraMichael Linenberger
Oct 22, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sergio GiraltSteven Devine

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.